Hai-dong N. Zhu
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 10, 2026
Intelligent metal-integrated hydrogels orchestrate pyroptosis and cGAS-STING for potentiated treatment of colorectal cancer peritoneal metastasis.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: May 19, 2026
Knowledge mapping of ⁹⁰Y transarterial radioembolization combined with immunotherapy in hepatocellular carcinoma: a bibliometric analysis.
Journal: Discover oncology
Published: March 06, 2026
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 24, 2026
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.
Journal: Alimentary pharmacology & therapeutics
Published: December 10, 2025
Should transarterial chemoembolization be applied with systemic therapy for hepatocellular carcinoma with hepatic vein and/or inferior vena cava tumor thrombus (CHANCE2505)?: a multicenter study.
Journal: International journal of surgery (London, England)
Published: September 16, 2025
Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation study.
Journal: EClinicalMedicine
Published: September 14, 2025
The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy Combinations.
Journal: Academic radiology
Published: September 12, 2025
TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysis.
Journal: European radiology experimental
Published: July 31, 2025
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).
Journal: Hepatology (Baltimore, Md.)
Published: July 13, 2025
Bilayer nanofiber-coated stent integrating internal radiation and spatiotemporal IL-12 release promotes antitumor immune response.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: June 27, 2025
A Study on Overcoming Post-TACE Drug Resistance in HCC Based on Controllable Oxygen Release-Magnetic Hyperthermia Therapy.
Journal: Advanced healthcare materials
Published: July 18, 2024
Last Updated: 09/26/2026